satisfaction of customary closing conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/

Under the terms of the Transaction, Chiesi will commence a tender offer to acquire all outstanding shares of KalVista for ￥27.00 per share in cash. The total value implied by the Transaction at closing is approximately ￥1.9bn. At Chiesi, initiatives in this area are spearheaded by Chiesi Global Rare Diseases, the Group’s business unit focused on research, development and commercialization of therapies for rare and ultrarare conditions.

The Transaction is Chiesi’s most substantial acquisition to date in value terms and reflects the company's longterm ambitions, and represents an important milestone in its strategy in Rare Diseases, reinforcing its commitment across generations to improving the lives of people living with rare conditions.

Upon completion of the Transaction, Chiesi will
=*=*=*=*=*=
当前为第2/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页